Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 505Urinary Bladder Neoplasms 139Carcinoma, Renal Cell 117Neoplasms 67Kidney Neoplasms 53Non-Muscle Invasive Bladder Neoplasms 43Neoplasm Metastasis 38Carcinoma, Transitional Cell 38Breast Neoplasms 30Testicular Neoplasms 28Recurrence 20Wilms Tumor 18Parkinson Disease 4, Autosomal Dominant Lewy Body 14Pain 13Ovarian Neoplasms 13Urologic Neoplasms 12Testicular Germ Cell Tumor 12Teratoma 12Seminoma 12Multiple Myeloma 12Burkitt Lymphoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Carcinoma, Ovarian Epithelial 11Carcinoma 11Urogenital Neoplasms 10Neuroblastoma 10Lymphoma, Non-Hodgkin 10Lymphoma, Mantle-Cell 10Lymphoma, Large-Cell, Immunoblastic 10

Interventions

masitinib 1Prednisone 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Metastatic Castrate Resistant Prostate Cancer × Genitourinary × Clear all
NCT03761225 2023-09-29

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

AB Science

Phase 3 Completed
714 enrolled
Genitourinary

Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡